Kapitalizam 101

yoyogi wrote:Pa kreni redom. Marks je bio katastrofalno u krivu misleći da se vrednost stvara u procesu rada. Ne na tržištu. To je umro a nije shvatio. Njegovo neshvatanje i njegova ideologija je bila porobila trećinu čovečanstva a pobila više nego Drugi svetski rat.

Pravi bilo šta, samo da su tu sirovine, rad, finalni proizvod. Kao u sicijalističkim ekonomijama, bezvredne fabrike koje su pravile proizvode lošeg kvaliteta koje su svi izbegavali. Pa smo išli u Trst da kupujemo odeću a u SFRJ su bile hiljade fabrika koje prave odeću koja je bila ružna.

Moj korisnik iz 1980-ih, "Obuća" Beograd, jedan mi reče da je njihov uspeh sa prodajom obuće u Rusiji (cipele) u tome da je sve na latinici.

U njegovu čast, kupio sam prve "brodarice" koje baš njegova firma napravila, otimajući se od cokula i borosana.

Funeral provider Dignity warns fall in number of deaths will hit profits https://t.co/ZzhVjSrkhq

— The Guardian (@guardian) May 13, 2019

In response to multiple discrimination lawsuits, Lyft argued that “it is not in the transportation business” and therefore should not be troubled by the Americans with Disabilities Act (ADA). Instead, Lyft argues, it is a technology company.
Might it be that Lyft is actually a transportation technology company? Presumably, they would loudly scoff at the idea but Lyft didn’t respond to a request for comment.

School made six-year-old girl do "cafeteria walk of shame" to return lunch because she didn't have enough money https://t.co/grvvVAG2CY

— Newsweek (@Newsweek) May 22, 2019

kapitalizam je dobro osmisljen sistem ali ovaj usa kapitalizam je totalitarni harac i samo lopovi, spekulanti, prevaranti i lucky adrenalin money junkies dobijaju. 

A potential cure for a lethal childhood disorder -- the first of its kind in the U.S. -- is hitting the market at a cost of $2.1 million, paving the way for more therapies that bring dramatic benefits for patients, along with challenges for health-care systems.

The U.S. Food and Drug Administration on Friday approved Novartis AG’s Zolgensma, a gene therapy targeting children under two years old who have a severe illness called spinal muscular atrophy. The Swiss drugmaker said it’s offering novel payment options, including spreading out the costs over time, refunds for patients whose treatment fails and discounts for insurers that provide swift coverage.